A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
At a glance
- Drugs Sergliflozin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Oct 2008 Actual start date changed from Dec 2005 to Jan 2006 as reported by Clinicaltrials.gov.
- 19 Jun 2007 Status changed from in progress to completed.
- 05 Nov 2006 New trial record.